Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 6, 2012, Pages 342-345

  Si, Dayong ^a   Wang, Juan ^a   Zhang, Yifan ^b   Zhong, Dafang ^b   Zhou, Hui ^a  

^a JILIN UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

CYP2C19*2; CYP2C9*13; haplotype; long range

Indexed keywords

CHLORPROPAMIDE; PHENYTOIN; TOLBUTAMIDE; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; CHINESE; CYP2C19 GENE; CYP2C9 GENE; DRUG CLEARANCE; DRUG METABOLISM; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN; CHI SQUARE DISTRIBUTION; CHINA; DNA SEQUENCE; ENZYME SPECIFICITY; GENETICS; METABOLISM; PHENOTYPE;

ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; CHINA; GENE FREQUENCY; HAPLOTYPES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; SUBSTRATE SPECIFICITY;

EID: 84866257247     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1804     Document Type: Article

References (26)

1. Rosemary J, Adithan C,. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2007; 2: 93-109. doi:10.2174/157488407779422302. (Pubitemid 46729082)
2. Bae JW, Kim HK, Kim JH, et al,. Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 2005; 60: 418-422. doi:10.1111/j.1365-2125.2005.02448.x. (Pubitemid 41428473)
3. Yin T, Maekawa K, Kamide K, et al,. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 2008; 31: 1549-1557. doi:10.1291/hypres.31.1549.
4. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ,. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010; 11: 781-791. doi:10.2217/pgs.10.49.
5. Xiong Y, Wang M, Fang K, et al,. A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China. Genomics 2011; 97: 277-281. doi:10.1016/j.ygeno.2010.11.004.
6. Bae JW, Choi CI, Kim MJ, et al,. Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacol Sin 2011; 32: 1303-1308. doi:10.1038/aps.2011.100.
7. Lee HW, Lim MS, Lee J, et al,. Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics. J Clin Pharm Ther 2012; 37: 105-111. doi:10.1111/j.1365-2710. 2010.01238.x.
8. Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D,. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004; 14: 465-469. (Pubitemid 38971236)
9. Guo Y, Zhang Y, Wang Y, et al,. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 2005; 33: 749-753. (Pubitemid 40686627)
10. Guo Y, Wang Y, Si D, Fawcett PJ, Zhong D, Zhou H,. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica 2005; 35: 853-861. (Pubitemid 41759171)
11. Li Z, Wang G, Wang LS, et al,. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects. Xenobiotica 2009; 39: 788-793.
12. Maekawa K, Harakawa N, Sugiyama E, et al,. Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects. Drug Metab Dispos 2009; 37: 1895-1903.
13. Zi J, Liu D, Ma P, et al,. Effects of CYP2C9*3 and CYP2C9*13 on diclofenac metabolism and inhibition-based drug-drug interactions. Drug Metab Pharmacokinet 2010; 25: 343-350.
14. Bae JW, Choi CI, Jang CG, Lee SY,. Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam. Br J Clin Pharmacol 2011; 71: 550-555. doi:10.1111/j.1365-2125.2010. 03853.x.
15. Choi CI, Kim MJ, Chung EK, et al,. CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. Eur J Clin Pharmacol 2012; 68: 149-154.
16. King BP, Khan TI, Aithal GP, Kamali F, Daly AK,. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 2004; 14: 813-822. (Pubitemid 40063603)
17. Maekawa K, Fukushima-Uesaka H, Tohkin M, et al,. Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics 2006; 16: 497-514. (Pubitemid 43922347)
18. Kramer MA, Rettie AE, Rieder MJ, Cabacungan ET, Hines RN,. Novel CYP2C9 promoter variants and assessment of their impact on gene expression. Mol Pharmacol 2008; 73: 1751-1760. (Pubitemid 351724362)
19. Chaudhry AS, Urban TJ, Lamba JK, et al,. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*, affect phenytoin autoinduction of clearance and maintenance dose. J Pharmacol Exp Ther 2010; 332: 599-611.
20. Lee SJ, Jang YJ, Cha EY, Kim HS, Lee SS, Shin JG,. A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients. Br J Clin Pharmacol 2010; 70: 213-221. doi: 10.1111/j.1365-2125.2010. 03688.x.
21. Walton R, Kimber M, Rockett K, Trafford C, Kwiatkowski D, Sirugo G,. Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10. Nat Genet 2005; 37: 915-916. (Pubitemid 43086140)
22. Saito Y, Maekawa K, Ozawa S, Sawada J,. Genetic polymorphisms and haplotypes of major drug metabolizing enzymes in East Asians and their comparison with other Ethnic populations. Curr Pharmacogenomics 2007; 5: 49-78. doi:10.2174/157016007780077202. (Pubitemid 46403580)
23. Suarez-Kurtz G, Genro JP, de Moraes MO, et al,. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharmacogenomics J 2012; 12: 267-276.
24. Pedersen RS, Brasch-Andersen C, Sim SC, et al,. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol 2010; 66: 1199-1205. doi:10.1007/s00228-010-0864-8.
25. Zhang Y, Si D, Chen X, et al,. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br J Clin Pharmacol 2007; 64: 67-74. doi:10.1111/j.1365-2125.2007.02846.x. (Pubitemid 46934414)
26. Desta Z, Zhao X, Shin JG, Flockhart DA,. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-958. (Pubitemid 35168437)